Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rae

Showing results (251-260 of 292) with videos related to

Pageof 30
Sort By:
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Breast Cancer Research and Treatment|November 6, 2015
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, N Lynn Henry, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897Christine B Ambrosone, William E Barlow, Wanda Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistanceMatthew P Goetz, Vera J Suman, Fergus J Couch, et al.
Journal of Medicinal Chemistry|August 30, 2023
Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor ActivityZhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyCesar A Santa-Maria, Amanda Blackford, Anne T Nguyen, et al.
Journal of the National Cancer Institute|January 6, 2005
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentYan Jin, Zeruesenay Desta, Vered Stearns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancerCostanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
Frontiers in Endocrinology|March 3, 2020
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer CellsAnna R Michmerhuizen, Benjamin Chandler, Eric Olsen, et al.
Pageof 30

Showing results (251-260 of 292) with videos related to

Sort By:
Pageof 30
JCI Insight|December 21, 2021
RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypesAndrea M Pesch, Nicole H Hirsh, Anna R Michmerhuizen, et al.
Breast Cancer Research and Treatment|November 6, 2015
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, N Lynn Henry, Kelley M Kidwell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2009
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897Christine B Ambrosone, William E Barlow, Wanda Reynolds, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistanceMatthew P Goetz, Vera J Suman, Fergus J Couch, et al.
Journal of Medicinal Chemistry|August 30, 2023
Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor ActivityZhixiang Chen, Biao Hu, Rohan Kalyan Rej, et al.
Molecular Oncology|May 15, 2016
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistanceCostanza Paoletti, Jose M Larios, Maria C Muñiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyCesar A Santa-Maria, Amanda Blackford, Anne T Nguyen, et al.
Journal of the National Cancer Institute|January 6, 2005
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentYan Jin, Zeruesenay Desta, Vered Stearns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 9, 2014
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancerCostanza Paoletti, Maria C Muñiz, Dafydd G Thomas, et al.
Frontiers in Endocrinology|March 3, 2020
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer CellsAnna R Michmerhuizen, Benjamin Chandler, Eric Olsen, et al.
Pageof 30